Silence Therapeutics granted two US patents

Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents.

Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents.

The patents, which are for both its interfering RNA molecules and lipid complexes used in drug delivery, will extend Silence's intellectual property in these areas of research.

Dr. Klaus Giese, Chief Scientific Officer of Silence, said: "These notifications from the USPTO further strengthens Silence's IP position in the arena of RNA interference (RNAi) therapeutics and builds upon the already strong proprietary technology Silence offers its partners. The broad range of RNAi therapeutics in terms of their possible length of base pairs again distinguishes Silence from competitors which provide coverage for only very few lengths, if any.

"We welcome the decision of the USPTO on drug delivery as an appreciation of Silence's contribution. With this patent, Silence is becoming an even more attractive partner for companies interested in the delivery of a variety of classes of compounds with siRNA and miRNA being only two of them."

The share price was down 6.25% to 3.15p by 13:18.

NR

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
6 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Best savings accounts – February 2023
Savings

Best savings accounts – February 2023

Interest rates on cash savings are making a comeback. We look at the best savings accounts on the market now
6 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
6 Feb 2023
Share tips of the week – 3 February 2023
Investments

Share tips of the week – 3 February 2023

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages
3 Feb 2023